惠氏藥廠所生產的「雷帕霉素」（Rapamune）是一種免疫抑制劑，主要在協助腎臟移植者排除器官排斥的症狀，美國食品藥物管理局（Food and Drug Administration，FDA）於2010年4月批准此款新藥。但惠氏因涉嫌廣告不實，被判高額的罰款。
惠氏藥廠所生產的「雷帕霉素」因涉嫌廣告不實，遭判罰4.9億元美金。翻攝網路
This entry passed through the Full-Text RSS service — if this is your content and you're reading it on someone else's site, please read the FAQ at fivefilters.org/content-only/faq.php#publishers. Five Filters recommends: 'You Say What You Like, Because They Like What You Say' - http://www.medialens.org/index.php/alerts/alert-archive/alerts-2013/731-you-say-what-you-like-because-they-like-what-you-say.html
You are receiving this email because you subscribed to this feed at blogtrottr.com.
留言列表
留言列表
